Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alignment Healthcare, Inc. (NASDAQ: ALHC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Medicare Advantage-focused health insurer. Alignment files annual and quarterly reports, along with current reports on Form 8-K, that describe its financial condition, operations and key developments in its Medicare Advantage business.
Recent Form 8-K filings show that Alignment uses these reports to announce quarterly financial results and share information discussed with investors and analysts. For example, the company has filed 8-Ks to furnish press releases on second and third quarter results and to outline discussions of strategy, market position and preliminary CMS Star Ratings. These filings often reference non-GAAP measures such as adjusted gross profit and adjusted EBITDA, which are defined and reconciled to the most comparable GAAP measures in accompanying tables.
Alignment’s SEC filings also provide detail on revenue sources and expenses. Condensed consolidated statements of operations list earned premiums and other revenue, along with medical expenses, selling, general and administrative expenses, and depreciation and amortization. Balance sheet information includes medical expenses payable, long-term debt and stockholders’ equity, giving investors a structured view of the company’s capital and obligations.
Through this page, users can track ongoing 8-K disclosures related to earnings releases, guidance updates, investor presentations and other material events. Filings may also reference CMS Star Ratings, membership expectations and risk factors summarized in the company’s Form 10-K and other periodic reports. Stock Titan enhances access to these documents with AI-powered tools that help explain terminology, highlight key sections and summarize lengthy filings, allowing investors to more quickly understand how ALHC reports its performance, membership trends and risk profile.
Andreas P. Wagner, Chief Human Resources Officer at Alignment Healthcare, Inc. (ALHC), reported an insider sale. The Form 4 shows a sale of 12,032 shares of the company's common stock on 08/25/2025 at a price of $16.47 per share, leaving Mr. Wagner with 192,043 shares beneficially owned after the transaction. The filing indicates the sale was made pursuant to a Rule 10b5-1 trading plan adopted on 03/11/2025.
Form 144 notice: An insider proposes to sell 12,032 shares of common stock of the issuer through Morgan Stanley Smith Barney LLC, with an aggregate market value of $190,586.88, and an approximate sale date of 08/25/2025 on NASDAQ. The shares were acquired as restricted stock units on 02/07/2025 and paid on that date. The filing discloses prior 10b5-1 plan sales by the same person on 06/11/2025 totaling 19,399 shares for gross proceeds of $296,042.27. The filer attests there is no undisclosed material adverse information.
Alignment Healthcare (ALHC) insider Form 4: The filing shows Hyong (Ken) Kim, identified as Chief Medical Officer and an officer of the company, reported an open-market sale of 24,800 shares of the issuer's common stock on 08/22/2025 at a reported price of $16 per share. After the sale, Mr. Kim beneficially owned 447,367 shares, held directly. The Form 4 notes the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on 03/14/2025. The form is signed by Christopher J. Joyce as attorney-in-fact on 08/22/2025.
Alignment Healthcare insider sale notice: The filing reports that 24,800 shares of Alignment Healthcare common stock are proposed for sale via Morgan Stanley Smith Barney, with an aggregate market value of $391,840, and an approximate sale date of 08/22/2025 on NASDAQ. The shares were acquired 03/06/2021 as pre-IPO shares issued in exchange for partnership units. The filer reports two prior 10b5-1 sales by Hyong J Kim on 08/11/2025 and 08/13/2025, each showing 18,600 shares sold generating gross proceeds of $270,425.40 and $279,608.22 respectively. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
Alignment Healthcare Chief Medical Officer Hyong (Ken) Kim reported the sale of 18,600 shares of the company’s common stock on 08/13/2025 under a Rule 10b5-1 trading plan adopted on 03/14/2025. The sales generated a weighted-average price of $15.0327 per share, with individual trades executed between $15.00 and $15.09. After the reported transactions, the reporting person beneficially owned 472,167 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person and discloses the plan adoption date and the price range for the multiple sales.
Alignment Healthcare insider sale under a 10b5-1 plan: Dawn C. Maroney, President and officer of Alignment Healthcare (ALHC), reported a planned disposition of 30,000 shares of common stock on 08/13/2025 at a weighted-average price of $14.9036 per share, executed under a Rule 10b5-1 trading plan adopted 11/25/2024. After the sale, Maroney beneficially owns 2,012,899 shares directly. The filing notes the sale prices ranged from $14.64 to $15.13 and that full allocation details by price will be provided on request.
General Atlantic and affiliated entities disclosed a shared beneficial ownership of 43,993,323 shares of Alignment Healthcare Class A common stock, representing 22.2% of the outstanding shares as of June 30, 2025. The percentage is calculated using the company figure of 198,031,417 shares outstanding reported in the company's quarterly report.
The stake is held across multiple reporting persons including General Atlantic, L.P., several GAP Coinvestments vehicles and General Atlantic (ALN HLTH), L.P. The filing states these affiliated entities may be deemed to share voting and dispositive power over the disclosed shares due to their organizational and partner relationships.
Alignment Healthcare insider disclosure shows Hyong (Ken) Kim, the companys Chief Medical Officer, sold 18,600 shares of common stock on 08/11/2025 at a weighted-average price of $14.539 per share under a Rule 10b5-1 trading plan adopted 03/14/2025. The filing reports Mr. Kim continues to directly beneficially own 490,767 shares after the transaction.
The Form 4 was signed by an attorney-in-fact on 08/13/2025 and notes the executed sale prices ranged from $14.42 to $14.61; the reporting person offers to provide detailed per-price sale counts on request.
Alignment Healthcare, Inc. (ALHC) disclosed a proposed sale of 18,600 common shares under Rule 144, with an aggregate market value of $272,304.00. The shares were originally acquired 03/26/2021 as pre-IPO issuances exchanged for partnership units. The filing names Morgan Stanley Smith Barney LLC as the broker and lists an approximate sale date of 08/13/2025. The notice also records a related 10b5-1 sale executed on 08/11/2025 generating $270,425.40 in gross proceeds. The filer affirms they are not aware of undisclosed material adverse information about the issuer.
Alignment Healthcare insider sale by CEO John E. Kao. The Form 4 discloses that Mr. Kao, who is both a director and the Chief Executive Officer, sold 180,000 shares of Alignment Healthcare common stock on 08/11/2025 pursuant to a Rule 10b5-1 plan adopted on 03/12/2025. The filing reports a weighted-average sale price of $14.5991 with prices in the range $14.42 to $14.80. Following the reported transactions, the filing shows 1,373,100 shares beneficially owned indirectly through the JEK Trust. The form also includes an entry listing 4,888,586 shares marked as disposed with no transaction date shown.
FAQ
What is the current stock price of Alignment Healthcare (ALHC)?
What is the market cap of Alignment Healthcare (ALHC)?
